Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Diagnostic Advances

World J Methodol. Sep 26, 2017; 7(3): 73-92
Published online Sep 26, 2017. doi: 10.5662/wjm.v7.i3.73

Table 2 Drugs raising serum creatinine concentration

Drug	Ref.
Drugs enhancing creatinine production
Fenofibrate	[161]
Vitamin D receptor activators	[162]
Drugs inhibiting tubular creatinine secretion
Cimetidine	[163]
Cobicistat	[164]
Dronedarone	[165]
Pyrimethamine	[166]
Salicylates	[167]
Trimethoprim	[168]

Citation: Alaini A, Malhotra D, Rondon-Berrios H, Argyropoulos CP, Khitan ZJ, Raj DSC, Rohrscheib M, Shapiro JI, Tzamaloukas AH. Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate. World J Methodol 2017; 7(3): 73-92
URL: https://www.wjgnet.com/2222-0682/full/v7/i3/73.htm
DOI: https://dx.doi.org/10.5662/wjm.v7.i3.73

Alaini A, Malhotra D, Rondon-Berrios H, Argyropoulos CP, Khitan ZJ, Raj DSC, Rohrscheib M, Shapiro JI, Tzamaloukas AH. Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate. World J Methodol 2017; 7(3): 73-92 [PMID: 29026688 DOI: 10.5662/wjm.v7.i3.73]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.